Volume | 104,790 |
|
|||||
News | - | ||||||
Day High | 5.285 | Low High |
|||||
Day Low | 4.95 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
MeiraGTx Holdings PLC | MGTX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
5.17 | 4.95 | 5.285 | 5.07 | 5.10 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1,356 | 104,790 | $ 5.05 | $ 528,672 | - | 3.49 - 8.35 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:48:02 | 1 | $ 5.61 | USD |
MeiraGTx Holdings PLC Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
323.07M | 63.60M | - | 14.02M | -84.03M | -1.32 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
MeiraGTx News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MGTX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 5.17 | 5.46 | 4.95 | 5.18 | 117,872 | -0.10 | -1.93% |
1 Month | 5.67 | 5.69 | 4.68 | 5.09 | 132,313 | -0.60 | -10.58% |
3 Months | 6.31 | 6.85 | 4.68 | 5.73 | 145,631 | -1.24 | -19.65% |
6 Months | 4.82 | 7.60 | 4.32 | 5.87 | 203,700 | 0.25 | 5.19% |
1 Year | 6.11 | 8.35 | 3.49 | 5.61 | 215,280 | -1.04 | -17.02% |
3 Years | 13.85 | 24.8948 | 3.49 | 9.91 | 183,755 | -8.78 | -63.39% |
5 Years | 18.36 | 30.23 | 3.49 | 12.36 | 167,039 | -13.29 | -72.39% |
MeiraGTx Description
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, United Kingdom, and European Union. |